FREEDOM COVID: Full-Dose Anticoagulation Cut Mortality

In an in-hospital anticoagulation trial, the primary COVID endpoint was missed, but a survival benefit was observed.

Related Keywords

New York ,United States ,India ,Hong Kong ,London ,City Of ,United Kingdom ,America ,Valentin Fuster ,Julia Grapsa ,World Heart Federation ,Academic Research Consortium ,Mount Sinai School Of Medicine ,Journal Of The American College Cardiology ,American College Of Cardiology ,American College ,World Heart ,Mount Sinai Hospital ,Latin America ,New England Journal ,Gregg Stone ,Mount Sinai School ,Thomas Hospital ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Anticoagulation Therapy ,Anticoagulant ,Anticoagulation ,Thromboembolism ,Hospitals ,Eintubation ,Factor Xa Inhibitors ,Low Molecular Weight Heparin ,Mwh Low Molecular Weight Heparin ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Acci ,